Source:http://linkedlifedata.com/resource/pubmed/id/20022992
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-2-5
|
pubmed:abstractText |
Context: Previous exposure to hypercortisolism due to Cushing's disease (CD) may adversely affect long-term metabolic and cardiovascular outcomes. In particular, metabolic and cardiovascular outcomes of patients with previous CD who require GH replacement have not been fully established. Objective: The aim of the study was to compare the prevalence and incidence of metabolic syndrome (Adult Treatment Panel III criteria), diabetes mellitus, cardiovascular disease, and cerebrovascular disease in GH-treated subjects with previous CD with GH-treated subjects with previous nonfunctioning pituitary adenoma (NFPA). Design: We conducted post hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 362 international centers (1995-2006). Subjects: We studied adult-onset GH-deficient subjects with previous CD (n = 160) or NFPA (n = 879). All subjects received GH replacement therapy and were GH naive at enrollment. Multiple pituitary deficits were prevalent in both groups. Main Outcome Measures: We measured the prevalence and incidence of metabolic syndrome, diabetes mellitus, cardiovascular disease, and cerebrovascular disease at baseline and at 3 yr, standardized for age and sex differences between groups. Results: Compared with subjects with previous NFPA, subjects with previous CD had a significantly greater 3-yr incidence of metabolic syndrome (CD, 23.4%; NFPA, 9.2%; P = 0.01), baseline (CD, 6.3%; NFPA, 2.2%; P < 0.01) and 3-yr (CD, 7.6%; NFPA, 3.9%; P = 0.04) prevalence of cardiovascular disease, and baseline (CD, 6.4%; NFPA, 1.8%; P = 0.03) and 3-yr (CD, 10.2%; NFPA, 2.9%; P = 0.01) prevalence of cerebrovascular disease. Conclusions: Previous hypercortisolism may predispose GH-treated, GH-deficient subjects with prior CD to an increased risk of metabolic syndrome, cardiovascular disease, and cerebrovascular disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1945-7197
|
pubmed:author |
pubmed-author:CavagniniFrancescoF,
pubmed-author:International HypoCCS Advisory Board,
pubmed-author:LambertsSteven W JSW,
pubmed-author:MelmedShlomoS,
pubmed-author:MoDaojunD,
pubmed-author:Pecori GiraldiFrancescaF,
pubmed-author:StrasburgerChristian JCJ,
pubmed-author:WebbSusan MSM,
pubmed-author:WoodmanseeWhitney WWW,
pubmed-author:ZimmermannAlan GAG
|
pubmed:issnType |
Electronic
|
pubmed:volume |
95
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
630-8
|
pubmed:meshHeading |
pubmed-meshheading:20022992-Adenoma,
pubmed-meshheading:20022992-Adult,
pubmed-meshheading:20022992-Aged,
pubmed-meshheading:20022992-Cardiovascular Diseases,
pubmed-meshheading:20022992-Cerebrovascular Disorders,
pubmed-meshheading:20022992-Female,
pubmed-meshheading:20022992-Human Growth Hormone,
pubmed-meshheading:20022992-Humans,
pubmed-meshheading:20022992-Male,
pubmed-meshheading:20022992-Metabolic Syndrome X,
pubmed-meshheading:20022992-Middle Aged,
pubmed-meshheading:20022992-Pituitary ACTH Hypersecretion,
pubmed-meshheading:20022992-Pituitary Neoplasms,
pubmed-meshheading:20022992-Prevalence
|
pubmed:year |
2010
|
pubmed:articleTitle |
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
|
pubmed:affiliation |
Department of Endocrinology, Hospital Sant Pau, Pare Claret 167, 08025 Barcelona, Spain. swebb@santpau.cat
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|